BPX-01: Completed Ph II enrollment
BioPharmX completed enrollment of 225 patients with moderate to severe inflammatory, non-nodular acne vulgaris in the double-blind, placebo-controlled, U.S. Phase IIb OPAL trial evaluating about 1 g of 1% or 2% BPX-01 topical gel once...
